ReviewJournal of biomedicine & biotechnology2010
Echinococcus multilocularis and its intermediate host: a model of parasite-host interplay.
Review in Journal of biomedicine & biotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 168 citations in OpenAlex.
- Assessment of Vascularity in Hepatic Alveolar Echinococcosis: Comparison of Quantified Dual-Energy CT with Histopathologic Parameters.PloS one · 2016Trial
- Human leukocyte extract enhances albendazole efficacy against Echinococcus multilocularis in mice by reducing parasitic microRNAs, myeloid and lymphoid immunosuppressive cells.PLoS neglected tropical diseases · 2026Article
- Long-Term Outcomes After Hepatectomy for Alveolar Echinococcosis in Immunosuppressed Patients.Pathogens (Basel, Switzerland) · 2026Article
- Increasing Case Numbers and Earlier Age at Diagnosis of Alveolar Echinococcosis: Insights from a 13-Year Retrospective Swiss Study.Pathogens (Basel, Switzerland) · 2026Observational
- Therapeutic effects of IL-33/ST-2 pathway inhibition combined with albendazole on hepatic fibrosis and immune regulation in alveolar echinococcosis: in vivo and in vitro evidence.Parasites & vectors · 2026Article
- Alveolar echinococcosis drives functional reprogramming of hepatic CD8Frontiers in cellular and infection microbiology · 2026Article
- TPEDCC-PEG-based photodynamic therapy exhibits potent therapeutic efficacy against echinococcosis by inducing oxidative stress and mitochondria-mediated apoptosis.PLoS neglected tropical diseases · 2025Article
- [Pathology of echinococcosis : A non-neoplastic tumour-like lesion of the liver].Pathologie (Heidelberg, Germany) · 2025Article
- MicroRNA expression dynamics in mouse liver at different stages of Echinococcus multilocularis infection.BMC genomics · 2025Article
- Blocking NKG2A in Echinococcus multilocularis infection partially relieves impairment of NK cell function of the host.Cellular and molecular life sciences : CMLS · 2025Article
- Article
- Phytic acid impairs macrophage inflammatory response in Echinococcus multilocularis infection.Communications biology · 2025Article
- The value of nomogram analysis in predicting pulmonary metastasis in hepatic alveolar echinococcosis.Scientific reports · 2025Article
- Spatiotemporal Transcriptomic Profiling Reveals the Dynamic Immunological Landscape of Alveolar Echinococcosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Immunological landscape of hepatic alveolar echinococcosis: A bibliometric analysis.World journal of hepatology · 2025Article
- Advances in Novel Diagnostic Techniques for Alveolar Echinococcosis.Diagnostics (Basel, Switzerland) · 2025Review
- High PD-1 and CTLA-4 expression correlates with host immune suppression in patients and a mouse model infected with Echinococcus multilocularis.Parasites & vectors · 2024Article
- Immunological Characteristics of Hepatic Dendritic Cells in Patients and Mouse Model with LiverTropical medicine and infectious disease · 2024Article
- Design of a novel EmTSP-3 and EmTIP based multi-epitope vaccine againstFrontiers in immunology · 2024Article
- Interaction between tissue-dwelling helminth and the gut microbiota drives mucosal immunoregulation.NPJ biofilms and microbiomes · 2023Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Host-parasite interactions in the E. multilocularis-intermediate host model depend on a subtle balance between cellular immunity, which is responsible for host's resistance towards the metacestode, the larval stage of the parasite, and tolerance induction and maintenance. The pathological features of alveolar echinococcosis. the disease caused by E. multilocularis, are related both to parasitic growth and to host's immune response, leading to fibrosis and necrosis, The disease spectrum is clearly dependent on the genetic background of the host as well as on acquired disturbances of Th1-related immunity. The laminated layer of the metacestode, and especially its carbohydrate components, plays a major role in tolerance induction. Th2-type and anti-inflammatory cytokines, IL-10 and TGF-beta, as well as nitric oxide, are involved in the maintenance of tolerance and partial inhibition of cytotoxic mechanisms. Results of studies in the experimental mouse model and in patients suggest that immune modulation with cytokines, such as interferon-alpha, or with specific antigens could be used in the future to treat patients with alveolar echinococcosis and/or to prevent this very severe parasitic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.